Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14876 - 14900 of 14939 in total
Experimental
Experimental
Doramapimod is a P38 MAP kinase inhibitor.
Investigational
Sarconeos is an activator of the MAS receptor.
Investigational
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Investigational
Experimental
Experimental
Experimental
PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational
Investigational
AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
Investigational
ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
Investigational
ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
Investigational
R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.
Investigational
Experimental
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Investigational
Displaying drugs 14876 - 14900 of 14939 in total